By vgreene, 10 July, 2019 EGFR mutation testing1 in never smokers or small bx specimens, or mixed histology2
By vgreene, 10 July, 2019 EGFR mutation testing in never smokers or small bx specimens, or mixed histology
By vgreene, 10 July, 2019 High-level MET amplification of MET exon 14 skipping mutation: Not indicated as routine stand-alone assay outside the context of a clinical trial; perform as part of a larger testing panel either initially or when routine EFGR, ALK, BRAF, and ROS1 testing
By vgreene, 10 July, 2019 KRAS1-2 prognostic; not indicated as routine stand-alone assay as a sole determinant of targeted tx; appropriate to include KRAS as part of larger testing panels performed either initially or when routine EFGR, ALK, BRAF, and ROS1 testing is negative2
By vgreene, 10 July, 2019 ERBB2 (HER2) molecular testing: Not indicated as routine stand-alone assay outside the context of a clinical trial; perform as part of a larger testing panel either initially or when routine EFGR, ALK, BRAF, and ROS1 testing is negative2
By vgreene, 10 July, 2019 RET molecular testing1,2 Not recommended as a routine stand-alone assay outside of context of clinical trial, but appropriate to include RET as part of larger testing panels performed either initially or when routine EGFR, ALK, BRAF, and ROS1 testing is n